Applies to HCV & ddRNAi as a platform technology.It's very technical and applies to different target genes/delivery/and other aspects etc.Sorry that's the best I can explain.
MKT The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint